Reducing PVL is Key for the Future of TAVI
Professor Jochen Wöhrle, from Ulm of University (Germany) explains how precise placement with Lotus Valve System and the option to completely reposition the valve translates into low PVL rates.
« Lotus™ is fully repositionable and fully retrievable which leads to a high degree of procedure success and also almost no mild paravalvular leak. »
Speakers: Prof. Lars Sondergaard, Dr. Ted Feldman and Dr. Matthias Götberg
Focusing on paravalvular leakage even in challenging anatomies, Prof. Lars Sondergaard, Dr. Ted Feldman and Dr. Matthias Götberg discuss the technical features of the Lotus™ valve system and how they translate into promising clinical outcomes. This could be crucial to follow in the future with the expected expansion of indications.
The Lotus valve is still a relatively new device and while the community continues to gain experience, a growing number of clinical publications show a decrease in pacemaker rates. These reports include the results presented by Dr. Götberg at EuroPCR where 8% ** of pacemaker rate was achieved on the last 50 patients.
A Transfemoral TAVI with Lotus™ valve :
Clinical Case from Clinique Pasteur Toulouse, France
Operators: Dr. D.Tchétché, Dr. B. Farah from the Clinique Pasteur, Toulouse, France
Published with permission of PCR www.pcronline.com
PCR London Valves highlights:
“Clinical evidence, real world practice”
Chairpersons: Dr. Ted Feldman, Prof. Axel Linke
Panellists: Dr. Keith Dawkins, Prof. Ian Meredith, Dr. Didier Tchétché,
Dr. Nicolas Van Mieghem
Dr. Blackman and Dr. Van Mieghem Discuss the Evolution of Paravalvular Leak with the Lotus Valve System
The issue of paravalvular leak (PVL) has been an Achilles heel of TAVI, which has been proven a predictor of mortality in patients with moderate or severe PVL1. Valves without a seal may allow leaks to occur between the diseased annulus and the valve frame. With the Lotus valve and it’s unique Adaptive Seal™ which expands to seal the annulus or LVOT, we have seen an improvement with PVL data showing virtually no moderate PVL2,3.